EDGAR·FLOW

Traws Pharma, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Traws Pharma reported Q3 2026 results with positive Phase 2a data for ratutrelvir (COVID treatment) showing symptom resolution comparable to PAXLOVID in 92 subjects with fewer adverse events, and successful tablet formulation for tivoxavir marboxil (influenza prevention). The company entered a $50M common stock purchase agreement with Roth Principal Investments on October 23, 2026 (non-binding right to sell; $0 drawn to date). Cash declined to $2.3M (Sept 30) from $3.8M (Dec 31); Q3 net loss $3.5M; 15.4M shares outstanding.
Why this rating

Clinical data is encouraging but pre-pivotal; $50M line materially extends runway (5× current cash). Relative to $9.8M market cap, lifeline is significant. Early-stage risk remains high.

Tradability signal
NO TRADE

No trade: price $0.27 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.26 ▼ 1.89%
at our read · unknown
$0.27
+10 min · unknown
$0.27 ▲ 1.51%
+30 min · unknown
$0.26 ▼ 1.89%
+1 hr · unknown
$0.25 ▼ 5.66%
+4 hrs · unknown
$0.25 ▼ 6.42%

The stock had already moved +1.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ TRAW · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.